Figure 3From: Evaluation of high-risk clinicopathological indicators in gastrointestinal stromal tumors for prognosis and imatinib treatment outcome ROC curve for modified NIH criteria versus tumor size sub-group, mitosis count sub-group and serosal invasion sub-group in prognostic indicator in test (A) and validation (B) cohort. (**, P < 0.01). Back to article page